Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Biliary Tract Neoplasms × telotristat ethyl × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Serotonin Syndrome 3 Neuroendocrine Tumors 3 Pancreatic Neoplasms 1 Diarrhea 1 Carcinoid Tumor 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 38 Cisplatin 30 Oxaliplatin 20 Capecitabine 16 Leucovorin 13 Fluorouracil 13 pembrolizumab 10 lenvatinib 10 durvalumab 10 Irinotecan 10 S 1 (combination) 7 Bevacizumab 7 tremelimumab 6 apatinib 5 Nivolumab 5 Trastuzumab 4 Injections 4 Docetaxel 4 trametinib 3 titanium silicide 3 irinotecan sucrosofate 3 envafolimab 3 camrelizumab 3 atezolizumab 3 Drug Therapy 3 zanidatamab 2 toripalimab 2 tislelizumab 2 surufatinib 2 pertuzumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03790111 2023-04-19

TELE-ABC

TerSera Therapeutics LLC

Phase 2 Terminated

53 enrolled 47 charts

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡